High-dose brachytherapy appears to be safe and effective as monotherapy in patients with intermediate- risk prostate cancer, according to results from a retrospective analysis. When percent positive biopsy cores exceeding 75% or clinical stage T2c disease were excluded, researchers found that high-dose brachytherapy as monotherapy resulted in a 5-year biochemical disease-free survival rate of 97.5%.

Abstract: Journal of Urology, January 2012.